Can-Fite BioPharma

Can-Fite BioPharma $CANF is a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver & inflammatory diseases.

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
https://t.co/2SeoZrBDAP
$CANF

[Can-Fite BioPharma @CanFitePharma]

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
https://t.co/JBkrgkwb8Y
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
https://t.co/vAS5ELcig5
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
https://t.co/PhqXaEjW5a
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
https://t.co/iPSyvXD18o
$canf

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
https://t.co/qpN5x941N9
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
https://t.co/DEDKvzjg6h
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
https://t.co/K1djHComE2
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
https://t.co/IBNOmQiSxJ
$CABF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
https://t.co/ojWxOz607h
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Provides Update on Clinical and Financial Status
https://t.co/1CG9oKblSQ
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
https://t.co/egNKPDpPvM
$CANF

[Can-Fite BioPharma @CanFitePharma]

Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
https://t.co/YqAPfrp4Y4
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
https://t.co/S5OxfyQ6Vj
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
https://t.co/ZI59Aww2HB
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
https://t.co/rAGMMNYicY
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Reports 2024 Financial Results and Clinical Update
https://t.co/ulkAFmSn9T
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
https://t.co/2a7YBRLuIO
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
https://t.co/4wvrv4imm2
$CANF

[Can-Fite BioPharma @CanFitePharma]

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
https://t.co/hiskcM17xc
$CANF